Abstract: The present invention comprises a shelf-stable, self-leveling, decorative surface coating product that is durable and easy to apply. The product allows for direct application to floor surfaces without the need for applying the decorative elements onsite. In certain embodiments, the product comprises of a selected resin, at least two dispersing agents, and a decorative filler material. Resins may include epoxy resin, polyurethane resin, polyaspartic resin, polyurea resin, polyester resin, or methyl methacrylate resin. Dispersing agents may include modified polyurethane and solutions of modified urea. Filler materials may include aluminum trihydrate, colorants, polyethylene terephthalate and cured polyester resin. Production of the decorative surface coatings involves adding a first dispersing agent to a resin, high-speed mixing, addition of a second dispersing agent, high-speed mixing, addition of a filler material, and high-speed mixing, all at ambient temperature.

Abstract: The present invention relates generally to the field of disorders of complement activation. More specifically, the present invention provides methods and compositions useful for diagnosing and treating atypical hemolytic uremic syndrome, antiphospholipid antibody syndrome and other disorders of the alternative pathway of complement activation. In one embodiment, a method comprises the steps of (a) incubating or contacting serum obtained from a patient suspected of having atypical hemolytic uremic syndrome (aHUS) with a glycosylphosphatidylinositol-anchored protein (GPI-AP) deficient cell line; and (b) performing a cell viability assay on the cells from step (a). In a specific embodiment, the method further comprises the step of diagnosing the patient as having aHUS based on a statistically significant increased difference of non-viable cells from the patient serum as compared to a control.

Abstract: The present invention relates generally to the field of disorders of complement activation. More specifically, the present invention provides methods and compositions useful for diagnosing and treating atypical hemolytic uremic syndrome, antiphospholipid antibody syndrome and other disorders of the alternative pathway of complement activation. In one embodiment, a method comprises the steps of (a) incubating or contacting serum obtained from a patient suspected of having atypical hemolytic uremic syndrome (aHUS) with a glycosylphosphatidylinositol-anchored protein (GPI-AP) deficient cell line; and (b) performing a cell viability assay on the cells from step (a). In a specific embodiment, the method further comprises the step of diagnosing the patient as having aHUS based on a statistically significant increased difference of non-viable cells from the patient serum as compared to a control.

Abstract: This disclosure relates, at least in part, to methods of eliminating adverse immune reactions in a subject in need thereof including those associated with autoimmune diseases, allergic reactions and transplant rejection, including administration of a lymphocytotoxic non-myeloablative amount of a oxazaphosphorine drug to the subject.